Stay updated on Neratinib±Fulvestrant in HER2+/ER+ Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Neratinib±Fulvestrant in HER2+/ER+ Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Neratinib±Fulvestrant in HER2+/ER+ Metastatic Breast Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3 on the page, indicating a new site build.
    Difference
    0.1%
    Check dated 2026-03-11T16:44:25.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    A new site revision (v3.4.2) was added to the record history. The funding-status notice and the previous revision entry (v3.4.1) were removed.
    Difference
    0.6%
    Check dated 2026-02-11T02:13:06.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    A site-wide funding-status notice was added and the page revision updated from v3.4.0 to v3.4.1.
    Difference
    0.6%
    Check dated 2026-02-03T23:59:57.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    UI changes to the history view include a glossary toggle, green highlights for additions, red highlights for deletions, and visible revision/version labeling. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    1%
    Check dated 2026-01-28T00:14:10.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    A new site revision (v3.3.4) was added, replacing the previous revision (v3.3.3). This change affects page metadata and does not modify trial data, status, or details.
    Difference
    0.1%
    Check dated 2026-01-14T01:52:53.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    The changes consist of adding Revision: v3.3.3 and removing HHS Vulnerability Disclosure and Revision: v3.3.2 from the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-12-23T17:33:45.000Z thumbnail image

Stay in the know with updates to Neratinib±Fulvestrant in HER2+/ER+ Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Neratinib±Fulvestrant in HER2+/ER+ Metastatic Breast Cancer Clinical Trial page.